Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0035 • ACR Convergence 2021
Bromodomain Protein-regulated Stress Response in Rheumatoid Arthritis Synovial Fibroblasts
Tanja Seifritz¹, Thomas Züllig¹, Larissa Moser¹, Oliver Distler², Caroline Ospelt¹ and Kerstin Klein³, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ³Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland
Background/Purpose: Hypoxia and subsequent oxidative stress are early events in the RA joint and contribute to the activation of synovial fibroblasts (SF). Small molecule inhibitors…
Abstract Number: 0101 • ACR Convergence 2021
Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States
Jessica Leung¹, Tara Anderson¹, Kathleen Dooling¹, Fenglong Xie² and Jeffrey Curtis³, ¹Centers for Disease Control, Atlanta, GA, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Persons with immune mediated Inflammatory diseases (IMIDs) are at increased risk of developing herpes zoster (HZ) and postherpetic neuralgia. In 2018, CDC recommended a…
Abstract Number: 0174 • ACR Convergence 2021
Imaging Neoangiogenesis in Rheumatoid Arthritis II (INIRA II): Whole-body Synovial Uptake of 99mTc-Maraciclatide Correlates with Power Doppler Ultrasound and Serum Neoangiogenic Biomarkers
Laura Attipoe¹, Sujith Subesinghe², Cristina Blanco Gil², Maria Opena², Kathryn Steel³, Sarah Ryan³, Sam Norton³, Mark Rosser⁴, Gary Cook³, Andrew P Cope³ and Toby Garrood², ¹Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ²Guy's and St Thomas' NHS Foundation Trust, London, ³King's College London, London, United Kingdom, ⁴Serac Healthcare, London, United Kingdom
Background/Purpose: 99mTc-maraciclatide (99mTc-M) (Serac Healthcare) is a radio-labelled tracer which binds with high affinity to integrin αvβ3, a cell-adhesion molecule up-regulated on neoangiogenic blood vessels.…
Abstract Number: 0274 • ACR Convergence 2021
Angiopoietin-Like Protein 4, Apolipoprotein C3 and Lipoprotein Lipase Axis in the Abnormal Lipid Profile of Patients with Rheumatoid Arthritis: Relation to Subclinical Atheromatosis
juan Carlos Quevedo¹, Laura de Armás-Rillo², Antonia de Vera-González³, Laura Cáceres¹, Cristina Almeida¹, Alejandra González-Delgado³ and Iván Ferraz-Amaro³, ¹Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain, ²Universidad Europea de Canarias, Santa Cruz De Tenerife, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increase in cardiovascular (CV) risk, attributed, among other factors, to the existence of an abnormal lipid profile.…
Abstract Number: 0292 • ACR Convergence 2021
Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis
Amir Razmjou¹, Jennifer Wang², Ani Shahbazian², Srinivasa Reddy³ and Christina Charles-Schoeman², ¹University of California Los Angeles Medical Center, Los Angeles, CA, ²Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ³David Geffen School of Meicine, UCLA, Los Angeles, CA
Background/Purpose: Lung disease in patients with rheumatoid arthritis (RA) is common and associates with significantly increased morbidity and mortality. Oxidative stress plays an important role…
Abstract Number: 0474 • ACR Convergence 2021
Correlation of Fibromyalgia Survey Questionnaire and Quantitative Sensory Testing Among Patients with Active Rheumatoid Arthritis
Meriah Moore¹, Beth Wallace², Jing Song³, Lutfiyya Muhammad⁴, Andrew Heisler⁵, Daniel Clauw¹, Marcy Bolster⁶, Wendy Marder¹, Tuhina Neogi⁷, Alyssa Wohlfahrt⁸, Dorothy Dunlop⁹ and Yvonne Lee⁹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³Northwestern University, Worthington, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Bronson Rheumatology Specialists, Kalamazoo, MI, ⁶Massachusetts General Hospital, Boston, MA, ⁷Boston University School of Medicine, Boston, MA, ⁸Tufts University School of Medicine, Boston, MA, ⁹Northwestern University, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) commonly demonstrate disordered pain processing, termed central sensitization (CS). CS is typically measured using quantitative sensory testing (QST), which…
Abstract Number: 0573 • ACR Convergence 2021
Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
Hafsah Nabi¹, Bente Glintborg², Anne Gitte Loft³, Oliver Hendricks⁴, Jens Kristian Pedersen⁵, Søren Andreas Just⁶, Rabiah Ahmed⁷, Kamilla Danebod⁷, Heidi Munk⁸, Ada Colic⁹, Asta Linauskas¹⁰, Dorte Vendelbo Jensen¹¹, Johnny Raun¹², Jolanta Grydehøj¹³, Louise Brot Christensen¹⁴, Natalia Manilo¹⁵, Niels Lomborg¹⁶, Salome Kristensen¹⁷, Frank Mehnert¹⁸, Niels Steen Krogh¹⁹ and Merete Hetland²⁰, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, ²COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Snderborg, Denmark, ⁵Section of Rheumatology, Department of Medicine, Svendborg Hospital – Odense University Hospital, Svendborg, Denmark, ⁶Section of Rheumatology, Dept. of Medicine, Svendborg Hospital, Svendborg, Denmark, ⁷Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen University Hospital, Glostrup, Copenhagen, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Department of Rheumatology, Zealand University Hospital, Køge, Denmark, ¹⁰Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark, ¹¹Department of Internal Medicine, Rønne Hospital, Rønne, Denmark, ¹²Department of Rheumatology, Sygehus Lillebælt, Fredericia, Denmark, ¹³Department of Rheumatology, Holstebro Hospital, Holstebro, Denmark, ¹⁴Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark, ¹⁵Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ¹⁶Department of Rheumatology, Vejle Hospital Lillebælt, Vejle, Odense C, Denmark, ¹⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁸Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ¹⁹ZiteLab ApS, Copenhagen, Denmark, Frederiksberg, Denmark, ²⁰DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark
Background/Purpose: In routine care, biosimilar to biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of…
Abstract Number: 0604 • ACR Convergence 2021
Disparities in Burden of Disease in Patients with RA Across Racial and Ethnic Groups
Jacqueline O’Brien¹, Sang Hee Park², Taylor Blachley¹, Maya Marchese¹, Nicole Middaugh¹, Xue Han², Keith Wittstock² and Leslie Harrold¹, ¹CorEvitas, LLC, Waltham, MA, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Prior research has shown that differences exist in disease activity and clinical outcomes for RA across racial and ethnic groups in the US.1 This…
Abstract Number: 0757 • ACR Convergence 2021
Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study
Paul Studenic¹, Aliaksandra Baranskaya², Stanley Cohen³, Nancy Shadick⁴, Christine Iannaccone⁵, Maria Dahl Mjaavatten⁶, Elisabeth Lie⁷, Tore Kvien⁸, Josef Smolen⁹, Daniel Aletaha¹⁰ and Helga Radner⁹, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Brigham and Women’s Hospital, Topsfield, MA, ⁶Diakonhjemmet Hospital, Haslum, Norway, ⁷Diakonhjemmet Hospital, Oslo, Nepal, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Medical University Vienna, Vienna, Austria
Background/Purpose: The patient global assessment (PGA), typically assessed as 'Considering all of the ways your arthritis has affected you, how do you feel your arthritis…
Abstract Number: 0799 • ACR Convergence 2021
Relationships of Rheumatology Care and Patient Experiences to Rheumatoid Arthritis Remission
Kelly O'Neill¹, Kathryne Marks², Pamela Sinicrope³, Cynthia Crowson⁴, Elena Myasoedova³ and John Davis³, ¹Rheumatoid Patient Foundation, Lutz, FL, ²Rheumatoid Patient Foundation, Boston, MA, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Remission is a well-established optimal outcome in rheumatoid arthritis (RA) treatment, yet a minority of patients reach this goal. There is not one recognized…
Abstract Number: 0817 • ACR Convergence 2021
Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13
Hubert MAROTTE¹, Maryse Assing², Nadir Mammar², Yves Brault³ and Bruno Fautrel⁴, ¹Rheumatology department - Unisersity Hospital of Saint-Etienne, Saint-Etienne, France, ²Inflammation & Immunology - Pfizer, Paris, France, ³Pfizer, Paris, France, ⁴Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
Background/Purpose: ReFLECT study has been carried out to investigate real life use of CT-P13, the first monoclonal antibody biosimilar to infliximab (IFX) originator.Methods: ReFLECT is…
Abstract Number: 0834 • ACR Convergence 2021
Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry
Anthony Sebba¹, Clifton Bingham², Vivian Bykerk³, Stefano Fiore⁴, Kerri Ford⁵, Jud C Janak⁶, Dimitrios Pappas⁶, Taylor Blachley⁶, Swapna Dave⁶, Joel Kremer⁷, Miao Yu⁶ and Ernest Choy⁸, ¹Division of Rheumatology, University of South Florida, Tampa, FL, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, ⁸CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: RA patients who fail to achieve treatment targets with conventional synthetic DMARDs (csDMARDs) can be treated with biologics. Randomized controlled trials (RCTs) have shown…
Abstract Number: 0968 • ACR Convergence 2021
Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas¹, Gerald Watts¹, Garett Dunlap³, Heather Faust¹, Karishma Rupani¹, Joseph Mears¹, Deepak Rao¹, Runci Wang⁴, Gregory Keras¹, Nida Meednu⁵, Jonathan Coblyn¹, Elena Massarotti¹, Derrick Todd¹, Andrew McDavid⁶, Jennifer Anolik⁵, Accelerating Medicines Partnership AMP: RA/SLE Network⁷, Kevin Wei¹, Soumya Raychaudhuri¹ and Michael Brenner⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard University, Somerville, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Rochester Medical center, Rochester, NY, ⁶University of Rochester, Rochester, NY, ⁷NIH/FNIH, Bethesda, MD, ⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: T cell-derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. While CD4 T cells have traditionally been assumed to be the…
Abstract Number: 1019 • ACR Convergence 2021
Cigarette Smoking Induces Post-translational Protein Modifications in Both in Vitro and in Vivo Models of Rheumatoid Arthritis-associated Interstitial Lung Disease
Alyssa Gregory¹, Corrine Kliment¹, Geoffrey Thiele², Michael Duryee², Ted Mikuls², Bryant England², Jill Poole² and Dana Ascherman³, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Cigarette smoking has been epidemiologically linked to the development of ACPA+ rheumatoid arthritis (RA) and, by extension, RA-associated interstitial lung disease (RA-ILD). Providing strong…
Abstract Number: 1160 • ACR Convergence 2021
Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
Diana Meyler¹, Sofia Pedro², Alan Erickson³, Patricia Katz⁴ and Kaleb Michaud³, ¹UNMC, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of California San Francisco, San Francisco, CA
Background/Purpose: Despite being used for more than 70 years as a conventional (cs) DMARD, very little is known about the overall side effect (SE) profile…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.